Latest Content

Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.

ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.

Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.

Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.

A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.

Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring remains a key consideration.

How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.

Why purpose is becoming the most important infrastructure in AI-driven health care technology.

Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.

CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.

Pfizer and J&J supply chain experts on why health authorities now ask not just whether your quality systems work — but how fast you can adapt.

As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.

Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.